Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well copanlisib works in treating patients with endometrial
cancer that has not decreased or disappeared, and the cancer may still be in the body despite
treatment (persistent) or has come back (recurrent). Copanlisib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.